| Keywords: |
survival; cancer survival; survival analysis; clinical trial; validation process; note; research design; brain tumor; glioma; methodology; brain neoplasms; antineoplastic agent; letter; reproducibility; quality control; reproducibility of results; drug effect; cancer research; gene expression regulation; tumor suppressor gene; statistical analysis; data interpretation, statistical; peer review; colon cancer; liver cancer; medical literature; protein p21; proto-oncogene proteins p21(ras); clinical trials; genes, p53; humans; human; priority journal; antineoplaston as2-1; hras protein, human
|
